An exclusive letter of intent for licensing of UC San Francisco’s stem cell injection technology prompts major changes at China’s Sitoa Global.
China-based Sitoa Global is making some big moves after landing an exclusive licensing contract with UC San Francisco, according to a company announcement.
Sitoa signed an exclusive letter of intent for UCSF’s “medical stereotactic device,” designed to streamline the therapeutic delivery of stem cells into the brain.
